Please login to the form below

Not currently logged in
Email:
Password:

MSD invests in FKD Therapies

MSD has taken an equity stake in the Finland based company, FKD Therapies, owned by former CEO of Ark Therapeutics Nigel Parker

MSD (known as Merck in the US and Canada) has taken an equity stake in the Finland based company, FKD Therapies. FKD Therapies, which has reserves of $16m, is a company started by Nigel Parker, the former chief executive of Ark Therapeutics.

This investment by MSD constitutes part of a deal that will see FKD Therapies develop MSD's gene therapy portfolio, which includes a possible treatment for bladder cancer.

The possible bladder treatment that FKD Therapies will be developing contains an adenovirus, which is designed to carry an interferon gene into the bladder wall cells. Here, it expresses a protein within the bladder, possibly increasing its ability to penetrate tumour cells.

MSD's gene therapy programmes for glaucoma surgery failure and the treatment of solid tumours were also available to develop.

20th September 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics